AVBCC 2026 and the work of making cancer care deliver value
The 2026 summit of the Association for Value-Based Cancer Care, scheduled for October 7–9 at the New York Athletic Club, presents an oncology system confronting a widening gap between scientific possibility and practical delivery. Its detailed agenda connects drug pricing, community practice economics, artificial intelligence, patient access, and the difficult task of measuring benefit. Across three days, a recurring question emerges: what must change so that better science reliably produces better care? This report examines the program’s themes and inferred priorities, then considers how the conference might evolve by 2029 as today’s proposed solutions face tests of implementation and accountability. AVBCC
GUEST AUTHOR: Chat GPT 6 Sol 6.1 High.
This analysis uses the supplied October 2 agenda. The meeting is a no-media event; the report describes scheduled topics and draws inferences from their organization, without reporting speakers’ remarks or session conclusions. File: AVBCC 2026 Agenda 10.2
That distinction matters. A lower drug price and a sustainable care system are related objectives, but achieving one does not automatically achieve the other. The agenda repeatedly raises the possibility that changes intended to improve affordability could destabilize the revenue supporting clinical infrastructure. The inferred priority is to make those dependencies visible and develop payment arrangements that support the actual work of care. The program does not establish that an era beyond average sales price payment has arrived; it asks how stakeholders should prepare for substantial changes to familiar economics.
Outcome contracts require agreement on who can deliver the outcome. Sessions on pharmaceutical contracting, legal structures, data limitations, and commercial use cases recur across Wednesday and Thursday. Their accumulation suggests frustration with the distance between announcing a value-based agreement and operating one. A contract needs a measurable endpoint, reliable data, an attribution method, and parties able to influence the result. The agenda’s separate examination of who owns the outcome makes this problem explicit.
The underlying difficulty is shared responsibility. A manufacturer supplies a therapy; clinicians select and manage it; patients need access, support, and the ability to continue treatment. A payment arrangement that assigns responsibility without accounting for these dependencies can create disputes rather than improvement. The scheduled contracting examples, including a private-sector application of an Oncology Care Model approach, offer a useful counterweight to broad forecasts. Their presence suggests a program interested in operational experience, although the agenda alone cannot establish whether any arrangement succeeded or produced net savings.
AI is being considered as infrastructure across the care journey. The breadth of AI programming is striking. Wednesday covers strategy, investment, payer applications, clinical pathways, and the movement from individual tools to practice infrastructure. Thursday extends the discussion into revenue cycle operations, specialty pharmacy, human judgment, and longitudinal patient data. Friday combines a demonstration showcase with the question of whether better measurement can make cancer care genuinely value-based.
This distribution suggests that AI’s perceived role is expanding beyond assistance with isolated tasks. The program explores whether it can connect treatment planning, monitoring, reimbursement, and evidence generation. That is a larger organizational proposition than automating documentation.
It also creates a demanding test of value. Faster billing, more complete records, and better symptom control are distinct achievements; evidence for one does not establish the others. The agenda’s attention to implementation, return on investment, security, and human partnership points toward scrutiny of the whole workflow. A reasonable inferred priority is to evaluate what changes after a tool is deployed, including the work it creates for clinicians and staff.
Measurement connects the technology discussion to payment reform. Wednesday’s review of the Oncology Care Model and Enhancing Oncology Model and Friday’s session on AI and digital quality measurement form a thread across the summit. The latter explicitly asks whether electronic health record data, electronic patient-reported outcomes, and oncology interoperability standards can make performance clinically meaningful, auditable, and actionable.
The important distinction is between observing expenditure and understanding care. Claims can describe paid services, but the questions raised elsewhere in the program concern treatment toxicity, delayed access, adherence, appropriate testing, and patient experience. Those issues require more clinical context.
Better measurement would have to guide a response: identifying a deteriorating patient early enough to intervene, detecting a missed testing opportunity, or determining whether a care model improves outcomes. The agenda presents measurement as a possible explanation for the limitations of earlier approaches. That remains a hypothesis, rather than a demonstrated account of why value-based oncology has struggled. Payment design, staffing, and responsibility still need to align with whatever the measures reveal.
Community oncology is the recurring test of whether innovation can scale. The program returns to community delivery through cell and gene therapies, radiopharmaceuticals, bispecific antibodies, oral medicines, molecular testing, and medically integrated pharmacy. The recurring concern is that scientific capability can advance faster than the infrastructure needed to use it safely and consistently.
Across these sessions, access becomes a practical question involving site readiness, staffing, financing, monitoring, distribution, and coordination. Approval and coverage are important milestones, but they do not complete that chain. A therapy must reach an appropriate patient through a service capable of managing it.
The sessions on technology-supported toxicity management and anticipatory monitoring connect directly to this problem. Moving treatment closer to home requires dependable escalation and clinical response, alongside data collection. Advanced-practitioner reimbursement and Friday’s physician compensation discussion add the workforce dimension: expanding access depends on paying and organizing the people who perform that work. The inferred priority is to build delivery capacity alongside therapeutic innovation.
Precision medicine faces both an implementation test and an evidence test. Wednesday’s session on biomarker testing for clinical trial eligibility, Thursday’s genomics-first care discussion, and Friday’s molecular medicine case studies identify failures along the route from specimen to treatment. Testing must be ordered, financed, completed, interpreted, and returned in time to affect a decision. Tissue insufficiency and fragmented workflows can interrupt that route before a promising result becomes useful.
The agenda also questions whether increasingly sensitive information necessarily improves care. Its examination of molecular residual disease surveillance asks about clinical utility and spending. The screening session sets out an evidence chain connecting detection to changed management, patient benefit, and possible harms.
These topics belong together. Appropriate testing can be underused while other applications remain insufficiently supported. The useful question is which test, for which patient, at which decision point, with what consequential action. Clinical trial access and routine-care evidence generation extend that inquiry beyond testing itself. The program’s separate attention to international research competition suggests concern about the system’s capacity to generate future evidence as well as apply existing knowledge.
Transparency is also a debate about power. Employers, benefit consultants, pharmacy benefit managers, group purchasing organizations, distributors, management services organizations, and risk-bearing care partners receive sustained attention. Sessions on ownership, direct contracting, intermediary value, and utilization management suggest a changing map of who controls cancer care and who is accountable for its results.
The tension is that additional organizations may supply capabilities practices need while also creating additional costs, contractual restrictions, or administrative layers. The agenda raises both possibilities. Its discussions of prior authorization alternatives and pathway organizations sharpen the question: if one form of utilization control recedes, which decisions move elsewhere, and who can challenge them?
Data adds another dimension. Wednesday’s pathway-to-value session explicitly considers whether the ability to demonstrate outcomes could favor larger networks over smaller practices. An inference follows: the same infrastructure that enables value contracts could make scale a condition of participation. Shared standards and accessible services may therefore matter to competition and practice independence, as well as technical interoperability.
The patient perspective broadens what counts as value. Patient-focused sessions appear throughout the program, from Wednesday’s assessment of the patient’s situation and unequal access to insider knowledge to Friday’s examination of the gap between institutional ratings and lived experience. Second opinions, financial assistance, survivorship, geriatric assessment, and site-of-care decisions make that perspective concrete.
Together, these topics challenge a definition of value confined to drug selection or episode spending. Timely expertise, manageable symptoms, continuity after treatment, and care suited to functional status can materially shape the patient’s experience. The prevention session on obesity and GLP-1 therapies also extends the program’s horizon toward future cancer burden, while posing scientific questions rather than settling them.
Patient-centeredness becomes most consequential when it changes an operating decision: which service receives funding, what triggers intervention, how treatment intensity is chosen, or whether a proposed cost saving introduces a new access barrier. The agenda’s repeated return to these issues suggests that affordability and patient benefit need to be assessed together.
Policy implementation receives attention alongside policy ambition. Scheduled CMS leadership discussions and multiple sessions on Medicare arrangements, drug pricing, and commercial insurance place government policy throughout the summit. The Medicare Part B effectuation working-group town hall is especially revealing because it addresses the machinery of implementation. Related 340B sessions examine claims identification, verification, financial transactions, and reconciliation.
These subjects show why policy design and policy delivery need separate examination. A pricing framework can leave difficult questions about acquisition costs, payment timing, information exchange, and disputes. The agenda’s inclusion of a working-group report and a regional collaborative readout suggests interest in organized work beyond the annual meeting. It does not establish that recommendations were adopted or problems resolved. It does indicate that the program makes room for the operational details through which policy becomes a daily reality for practices and patients.
A 2029 conference could put results under greater scrutiny. The following possibilities are projections from the 2026 agenda, rather than announced plans or predictions of particular policy outcomes.
AI could move from demonstrations to comparative evaluation. A more mature program might ask which deployments reduced treatment delays, improved toxicity management, or saved staff time after accounting for oversight and integration. Sessions could compare sustained results across settings and examine failures, model changes, and the ability to audit recommendations. Demonstrations would remain useful, but would sit beside evidence of clinical and operational performance.
Outcome contracting could be judged through completed experience. Instead of concentrating on contract design, the conference might examine settlement results, attribution disputes, administrative costs, and patient outcomes. A crucial question would be whether savings survive after paying for the data, navigation, monitoring, and clinical infrastructure used to produce them. Contracts that endure would provide more informative examples than announcements alone.
Community delivery could become a measurable system capability. The discussion might move toward the proportion of eligible patients actually receiving complex therapies, geographic access, treatment delays, and safety across sites. That would allow scrutiny of whether community expansion improves access and lowers total costs while maintaining quality. Readiness assessments could become more specific about staffing, response capacity, and financial exposure.
Diagnostic debates could become more indication-specific. Molecular surveillance and screening sessions might distinguish applications supported by evidence of useful changes in management from those still requiring validation. Genomics-first care could be evaluated through testing completion, turnaround, treatment selection, and trial access. Stronger evidence could justify expansion in some settings and more selective use in others.
Practice sustainability and patient benefit could be evaluated together. A 2029 agenda might compare payment arrangements that explicitly finance navigation, monitoring, survivorship, and multidisciplinary care. It could also examine whether shared data infrastructure enables smaller practices to participate or whether the cost of demonstrating value increases concentration. Patient-facing measures would help assess what these organizational changes accomplish.
The strongest inference from the 2026 program is that oncology’s value problem spans several connected systems. Useful measurements need a clinical response; that response needs staff and financing; contracts need dependable data and defensible responsibility. By 2029, the conference could have a more concrete basis for judging whether these pieces work together. Its most informative reports would show who received better care, what made the improvement possible, and whether the arrangement can last.
Source and organization links: This report is based on AVBCC 2026 Agenda 10.2.docx, dated October 2, 2026. See the Association for Value-Based Cancer Care, the 2026 conference page, and the online agenda. The supplied agenda is the source for the session analysis; the online version may differ.
